Bioprocessing - Upstream & Downstream

How can manufacturing be improved for viral vectors?

Sitting Down With… Mike McMullen, President and CEO, Agilent Technologies, Santa Clara, California, USA.

How are industry and academia collaborating to tackle neglected diseases?

Let’s reduce gene therapy manufacturing costs by optimizing cell lines, improving transfectants, and optimizing downstream purification.

Digital technology, data analytics and continuous processing. The world of biopharma is changing rapidly.

It is time to rethink traditional approaches to biosafety.

We must never forget unmet needs when developing new medicines.

After a vibrant year of advances in pharmaceutical development and manufacturing technologies, we present The Medicine Maker 2019 Innovation Awards.

More complex proteins are coming down the pipe! Next-generation protein expression will require a toolbox of next-generation solutions.

With the focus on next generation bioprocessing, it is important that manufacturers do not forget to re-examine their approach to viral safety.